Abstract: Endometrial stromal sarcoma (ESS) accounts for approximately 20% of all uterine sarcomas and presents, at a mean age, around 50 years of age. Half of the patients are premenopausal. ESS often manifests as an endometrial polyp and 60% of cases present with FIGO stage I disease. The natural history is one of slow growing indolent disease. Typical microscopic findings include a uniform population of endometrial stromal-type cells invading the myometrium and myometrial vessels. Imaging studies cannot reliably diagnose ESS preoperatively, so surgical resection for a presumed fibroid is a common scenario. Hysterectomy is the cornerstone of treatment for localized ESS, but morcellation should be avoided. Systematic lymphadenectomy in ESS does not improve the outcome. Leaving the ovaries in situ does not worsen survival and this is of importance especially for young women. The data support the current practice to administer adjuvant hormonal treatment, although several questions remain, such as optimal doses, regimens (progestins or aromatase inhibitors) and duration of therapy. Repeat surgery for recurrent disease that is indolent and hormone sensitive appears to be an acceptable approach. Systemic treatment for recurrent disease is mainly hormonal.
A part from the most common epithelial cancers, endometrial stroma or myometrial smooth muscle may give rise to mesenchymal tumors. 1 In the United States, uterine sarcomas represent 8% of all uterine cancers, 2 and they constitute 7% of all soft tissue sarcomas. 3 In a Norwegian study that excluded endometrial carcinosarcoma, the most common sarcoma types were leiomyosarcoma (63%) and endometrial stromal sarcoma (ESS) (21%), whereas undifferentiated endometrial sarcoma (6%) and adenosarcoma (6%) were uncommon. 4 Uterine sarcomas can be low grade (ESS, adenosarcoma) or high grade (leiomyosarcoma, adenosarcoma with sarcomatous overgrowth, undifferentiated endometrial sarcoma). High-grade uterine sarcomas are explained in a separate guideline because they differ in pathology, clinical behavior, and management.
Historically, uterine sarcomas were staged as endometrial carcinomas, with no separate classification. Recently, a new staging system for ESS has been published by the International Federation of Gynecology and Obstetrics (FIGO) 5 ( Table 1) .
The main symptom of ESS is abnormal uterine bleeding. In addition, pelvic or abdominal discomfort is frequently noted. Physical examination may indicate an enlarging uterus or a mass or polyp visible on speculum examination. In some cases, pulmonary metastases are noted at primary diagnosis.
EPIDEMIOLOGY
Endometrial stromal sarcoma accounts for approximately 20% of all uterine sarcomas, with an incidence of one third of that of uterine leiomyosarcoma and at a mean age around 50 years. 4, 6 Half of the patients are premenopausal. Obesity, diabetes, and younger age at menarche have been associated with increased risk of ESS, although the molecular mechanisms involved are yet to be elucidated. 7 In addition, tamoxifen intake is associated with ESS development. 8 It can often manifest as an endometrial polyp, such that endometrial biopsy is more likely to be diagnostic than for leiomyosarcoma. Most cases (60%) present with FIGO stage I disease, with only 20% presenting with stage IV metastatic disease. 6 The natural history is 1 of the slow-growing indolent diseases, and this is reflected by good outcomes, with a large population-based study of 831 patients reporting a 5-year disease-specific survival of more than 90% for all stages 6 and a smaller patient series of 85 patients reporting 5-year and 10-year crude survival rates of 84% and 77% for stage I disease. 9 However, late relapses are relatively common, requiring relatively long followup for these patients.
PATHOLOGY Diagnosis
Endometrial stromal neoplasms can be either benign (endometrial stromal nodule [ESN]) or malignant (ESS). Endometrial stromal sarcoma behaves as a low-grade sarcoma, with the potential for recurrence and metastasis. 10 Endometrial stromal nodules have a circumscribed contour, many are polypoid and protrude in the uterine cavity. Endometrial stromal sarcoma usually involves the endometrium, sometimes extensively. 11 It forms soft tan smooth-surfaced polyps that are occasionally partly infarcted and hemorrhagic. 11 Endometrial stromal neoplasms are exclusively composed of cells resembling the endometrial stroma in its proliferative phase. The rare ESN has well-circumscribed borders, 12, 13 whereas ESS represents the same histological entity but with infiltrating borders. 10 Typical microscopic findings include a uniform population of endometrial stromal-type cells invading the myometrium and myometrial vessels. Until recently, ESS was subdivided into low-grade and high-grade tumors on the basis of mitotic count. 12 However, high-grade tumors lack the typical growth pattern and vascularity of ESS and show destructive myometrial invasion rather than the lymphatic permeation of ESS. Moreover, they demonstrate marked cellular pleomorphism and brisk mitotic activity. As a result, the term ESS is now restricted to malignancies that were formally referred to as low-grade ESS. 10, 13 Imaging modalities are unreliable in making a preoperative diagnosis of ESS. Nevertheless, some characteristics of ESS can be identified. 1 On ultrasonography, it may present as hypoechogenic masses with irregular margins in the endometrium with an irregular or circular vascularization pattern on Doppler or a heterogeneous mass. 1 On magnetic resonance imagining (MRI), ESS typically presents as an invasive endometrial mass with extensive myometrial involvement, which is either sharply demarcated or diffusely infiltrative. On T2-weighted images, bands of low signal intensity corresponding to preserved bundles of myometrium are observed within areas of myometrial involvement. Another common MRI finding in ESS is tumor extension along the vessels or ligaments. In a comparative MRI study of 8 cases of ESS and 21 consecutive cases of endometrial carcinoma, Ueda et al concluded that ESS more frequently had irregular margins, nodular lesions at the margin, intramyometrial nodular extension, and formation of multiple nodular 14 Endometrial stromal sarcoma often shows intense 18 FDG uptake, and PET and the combined use of PET with CT are promising for diagnosis. There is a need for more effective imaging techniques to improve the accurate preoperative diagnosis of ESS. Because ESS can present with distant metastasis even at initial diagnosis, preoperative imaging of the chest and abdomen may be considered.
MOLECULAR BIOLOGY AND GENETICS
Endometrial stromal sarcoma is characterized by a chromosomal translocation t(7:17)(p15;q21), which results in the juxtaposition of 2 zinc finger genes JAZF1 and JJAZ1 resulting in the JAZF1/JJAZ1 fusion gene. One study found the translocation in 7 of 7 cases of ESS and 3 of 3 cases of ESN. 15 Subsequent studies have confirmed these findings, with translocations detected in 8 of 16 cases of ESS, 4 of 4 cases of ESN, 16 and 6 of 12 cases of ESS. 17 The presence of the translocation in ESN suggests that ESS may arise from a progression of a benign stromal proliferation. However, the lack of the translocation in most cases of undifferentiated endometrial sarcoma suggests that this disease may not always be due to malignant progression of ESS, but via a distinct pathogenetic mechanism in at least some cases. Although only approximately half of ESS cases have the JAZF1/JJAZ1 translocation, 2 other fusion genes have now been identified as associated with ESS, JAZF1/PHF1, and EPC1/PHF1. 18 Recently, a new fusion protein (YWHAE-FAM22) has been identified. 19 In contrast to classic ESS, harboring JAZF1 genetic fusions, YWHAE-FAM22 ESS displays high-grade histologic features, a distinct gene expression profile, and a more aggressive clinical course. Fluorescence in situ hybridization analysis demonstrated absolute specificity of YWHAE-FAM22A/B genetic rearrangement for high-grade ESS, with no fusions detected in other uterine and nonuterine mesenchymal tumors (55 tumor types, n = 827). These discoveries reveal diagnostically and therapeutically relevant models for characterizing aberrant 14-3-3 oncogenic functions. Figure 1 summarizes the treatment strategy for earlystage and recurrent ESS.
INITIAL TREATMENT
1 Surgery with hysterectomy, either open or by a minimal invasive technique, is the cornerstone of treatment for localized ESS. 1, 20 Imaging studies cannot reliably diagnose ESS preoperatively; surgical resection for a presumed fibroid is a common scenario. This can result in inadvertent tumor morcellation of ESS, a technique used for presumed benign disease, which has an adverse impact on the patient outcomes. 21, 22 Although in the case-control series of Park et al, 22 including a total of 50 patients where morcellation resulted in a higher rate of abdominopelvic recurrences, patients could be salvaged by surgical resection such that 5-year overall survival was equivalent for patients undergoing hysterectomy or morcellation (83% vs 92%, P = 0.9). This study is likely to be underpowered to detect a difference. Most would support that ideally patients should undergo complete resection with hysterectomy to ensure an optimal outcome.
The benefit of lymphadenectomy for ESS is a controversial issue. The lymphatic system is commonly involved in ESS because the invasion of lymphatic vessels is a pathognomonic microscopic characteristic, as exemplified by the prior pathologic designation of endolymphatic stromal myosis. Nodal involvement designates a higher stage of disease and results in a worse outcome. 6 The incidence of lymph node metastases in ESS is generally low, with rates of 9.9% (28/282) 6 and 7% (7/100) 23 in recent series. Dos Santos et al reported a higher rate of 19% (7/36) but noted that involved nodes were obviously enlarged or associated with other gross extrauterine disease. In 20 patients with uterus-limited disease and grossly normal lymph nodes, only 2 (10%) had lymph node metastases. 24 Systematic lymphadenectomy in ESS does not appear to confer a therapeutic benefit. 6,23Y25 Although prospective studies are lacking, it seems that routine lymphadenectomy is not indicated unless lymph nodes are pathologically enlarged on preoperative imaging studies and as part of a cytoreductive procedure. Only a randomized study is able to clarify the role of lymphadenectomy.
Traditionally, the ovaries were removed because ESS typically expresses estrogen and progesterone receptors, and there were concerns of higher relapse rates if the ovaries were retained. Although this issue has less importance in perimenopausal and postmenopausal women, bilateral oophorectomy deserves particular consideration in young premenopausal women. In contrast to previous belief, it appears in small 25,27Y30 and large 6, 23 series that leaving the ovaries in situ does not worsen survival. Oncological outcome aside, maintenance of quality of life is important, and certainly management of menopausal symptoms may be challenging in young women undergoing oophorectomy. This is particularly the case as hormone replacement therapy has been associated with higher FIGURE 1. The treatment strategy for early-stage and recurrent ESS.
1 *Retention of the ovaries can be considered in young women with small ESS. †Adjuvant hormonal treatment can be considered.
relapse rates in 1 series with 5 patients, such that it is generally contraindicated in ESS patients. 28 Withdrawal of estrogen replacement therapy or tamoxifen can lead to stable disease, whereas progestins and aromaratase inhibitors are suggested to be very effective in disease control. 31 There is a very high rate of hormone receptor positivity in ESS, up to 100% in some series, 1 which has led to interest in using hormonal therapies for both advanced disease and adjuvant therapy in early-stage disease. 32 The use of adjuvant hormonal therapy has been reported in several studies. A small study reported on 22 patients with ESS, of whom 31% (4/13) of patients receiving adjuvant progestins recurred, compared with 67% (6/9) recurrence in patients who did not receive hormonal therapy. 28 Another study that included 30 ESS patients who received adjuvant hormones showed a nonsignificant trend to improved overall survival of 97 months for patients receiving hormonal therapy as compared with 72 months for those who did not (P = 0.07). 33 A recent report, summarizing data on the use of aromatase inhibitors, found an overall response rate of 67% in a total of 28 ESS patients. 32 The data support the current practice in some centers to administer adjuvant hormonal treatment. This seems reasonable, given that hormonal therapies are generally well tolerated. However, several questions remain, such as optimal doses, regimens (progestins or aromatase inhibitors), and duration of therapy. Most clinicians would consider progestins as the standard of care in this disease. Endometrial stromal sarcoma is not an approved indication for aromatase inhibitors. Although some consider a 2-year duration of hormonal treatment sufficient in the absence of solid data, others believe that the treatment should be livelong. Uterine-sparing surgery in young women is experimental. Four case reports are described. Although 2 women conceived and had a normal pregnancy, 1 patient presented with transperitoneal spread. In addition, 4 patients (G35) with a stage IA disease are currently on progestin therapy after myomectomy/polypectomy (personal communication by Stefano Greggi).
METASTATIC DISEASE AND RELAPSE
The benefit of cytoreductive surgery in locally advanced ESS is controversial, with little published evidence to support the practice. However, knowledge of tumor biology and natural history (indolent disease with primarily transperitoneal spread) suggests that cytoreductive surgery might be beneficial because of the low-grade nature of the disease and the efficacy of additional hormonal therapy. 28, 33, 34 If the ovaries were previously left in situ, they need to be removed when recurrence is obvious. Extensive surgery with organ resection (eg, splenectomy, bowel resection) can be considered, particularly if this contributes to achieving complete resection with no residual tumor. 1 However, the impact of resection of locally advanced disease on prolongation of survival is not proven, and so the decision to undertake extensive resection should be taken on an individual patient basis, depending on the relative morbidity of such surgery.
A series studying the benefit of adjuvant hormonal treatment in 31 ESS patients also included information according to stage. 25 The authors showed the benefit for patients with stage III/IV disease, of whom only 1 of 5 patients receiving adjuvant hormonal therapy relapsed as compared with 3 of 4 who relapsed having not received adjuvant therapy, concluding that adjuvant hormonal therapy lowered recurrence rates and improved overall survival. Recurrences of ESS are common even in early-stage disease, with a predilection for the lungs and abdomen. Relapse can occur in 36% to 56% of patients with early-stage disease, with a median time to recurrence of 65 and 9 months for stages I and III-IV, respectively. 10, 28, 35 Although valid data are lacking, repeat surgery for a disease that is indolent and hormone sensitive seems to be an acceptable approach. Secondary and tertiary cytoreductive procedures, including resection of distant metastases, should be considered. Intervals between surgeries can be extended by the addition of hormonal therapies.
There are a number of case reports showing responses to progestins, gonadotrophin-releasing hormone agonists, and aromatase inhibitors. Small series have provided further evidence for efficacy, with 7 of 8 patients treated with progestins responding and half of the patients achieving a complete response, and 6 of 7 patients responding to progestins or aromatase inhibitors for long durations up to 124 months. The largest published series to date describes 30 patients with recurrent ESS treated with hormonal therapy (megestrol acetate in 28 of 30, aromatase inhibitors in 3 of 30, leuprolide in 3 of 30, and mifepristone in 3 of 30) until disease progression. Five patients (17%) achieved a complete response, 3 (10%) achieved a partial response, 16 (53%) achieved stable disease, and 6 (20%) had disease progression. The median time to progression was 24 months. These data suggest that hormonal therapies are effective for metastatic disease. A lack of important adverse effects allows administration for longer periods.
The data on the response of ESS to chemotherapy are scarce because the literature dates from the era where highgrade and low-grade ESS were pooled. The combination of doxorubicin T dacarbazine in advanced gynecological sarcomas resulted in an 18% to 20% response rate in the ''other'' sarcoma group (of which 73% were ESS). 36 Piver et al reported on patients with recurrent ESS, including 2 patients who had durable responses to doxorubicin, methotrexate and megestrol acetate, and doxorubicin and chlorambucil, respectively. However, another 10 patients failed to respond to chemotherapy. 35 More recently, Cheng et al reported on 10 patients with recurrent ESS who received a range of chemotherapy regimens including doxorubicin, gemcitabine and docetaxel, actinomycin D, and paclitaxel and liposomal doxorubicin. Four patients achieved stable disease, but 6 showed disease progression, with a median time to progression of 6.5 months. 38 Thus, response rates to chemotherapy are low, and chemotherapy should only be prescribed when the armamentarium of hormonal therapies has become ineffective.
RADIOTHERAPY
Adjuvant pelvic radiotherapy does not influence overall survival because ESS typically recurs distantly. Although a modest benefit in locoregional control can be achieved by postoperative radiotherapy, overall survival is not improved. 35 Palliative radiotherapy can be used for recurrent or metastatic ESS when symptoms of local disease reduce the quality of life. When systemic treatment and/or surgical resection insufficiently reduce symptoms, radiotherapy is a valuable option. Overall, however, the role for radiotherapy is limited.
PERSPECTIVES
Studies within the framework of the IRCI (International Rare Cancer Initiative) may significantly improve our insight in clinical issues. Progress in medical treatment of uterine sarcomas will benefit from the in-depth investigation of tumor biology from specimens collected within the framework of clinical trials.
